Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, talks on the Phase III monarchE (NCT03155997) trial which investigated abemaciclib in participants with high-risk, node positive, early stage, hormone receptor positive (HR+), HER2-negative, breast cancer. 11% of patients in a cohort of over 5000 were eligible for adjuvant abemaciclib, characterized by young age and BRCA2 mutations, meaning this patient population may also be eligible to receive olaparib as adjuvant treatment. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.